Ocugen Completes Early Dosing for Stargardt Disease Gene Therapy Trial

Topline results expected in 2Q27 with BLA to follow by mid-2027 for potential first-in-class treatment

Apr. 1, 2026 at 11:35am

Got story updates? Submit your updates here. ›

Ocugen, Inc. announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST (AAV5-hRORA), a modifier gene therapy candidate developed for all Stargardt disease (ABCA4-associated retinopathies). The trial enrolled 63 participants, with the primary objective to evaluate the reduction in atrophic lesion size at 12 months.

Why it matters

Stargardt disease is a devastating pediatric-onset retinal disorder affecting approximately 100,000 patients in the U.S. and Europe, with no approved therapies to date. OCU410ST represents a potential first-in-class, one-time modifier gene therapy that could slow lesion growth, preserve visual function, and alter the course of this blinding disease.

The details

The GARDian3 trial is a multicenter, randomized, masked, pivotal Phase 2/3 study designed to evaluate the efficacy and safety of OCU410ST. Subjects randomized to the treatment group received a one-time subretinal injection of OCU410ST, while the untreated control group did not receive any treatment. Key endpoints include reduction in atrophic lesion size, improvements in visual acuity, and preservation of the Ellipsoid Zone. Interim analysis will be performed in Q3 2026, and data from the one-year follow-up will support Ocugen's planned Biologics License Application (BLA) submission by mid-2027.

  • Dosing completed in less than nine months.
  • Topline results expected in 2Q27.
  • BLA submission planned for mid-2027.

The players

Ocugen, Inc.

A pioneering biotechnology leader in gene therapies for blindness diseases, developing OCU410ST as a potential first-in-class, one-time modifier gene therapy for Stargardt disease.

Dr. Shankar Musunuri

Chairman, Chief Executive Officer, and Co-founder of Ocugen.

Dr. Huma Qamar

Chief Medical Officer of Ocugen.

Christine Kay, MD

Vitreo Retinal Associates, Florida and a principal investigator in the GARDian3 trial.

Got photos? Submit your photos here. ›

What they’re saying

“This enrollment milestone for a pivotal trial underscores the tremendous progress our team is making toward bringing a transformative therapy to people living with multiple ABCA4- related gene mutations including Stargardt disease.”

— Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen

“I am encouraged by the enthusiastic response and rapid enrollment in the GARDian3 registrational clinical trial for Stargardt disease—a devastating pediatric-onset retinal disorder affecting approximately 100,000 patients in the U.S. and Europe.”

— Dr. Huma Qamar, Chief Medical Officer of Ocugen

“The opportunity to intervene at an early stage of disease with a one-time subretinal gene therapy like OCU410ST that can potentially slow lesion growth, preserve visual function over time, and save vision before irreversible damage represents an exciting and much needed shift from watching patients decline to proactively altering the course of their disease.”

— Christine Kay, MD, Vitreo Retinal Associates, Florida and a principal investigator in the GARDian3 trial

What’s next

Interim analysis will be performed in the third quarter of 2026 when 24 subjects complete the 8-month follow-up visit post-OCU410ST treatment. Data from the one-year follow-up will be used to support the company's planned Biologics License Application (BLA) submission by mid-2027.

The takeaway

The rapid enrollment and completion of dosing in the GARDian3 trial for OCU410ST, a potential first-in-class gene therapy for Stargardt disease, underscores the significant unmet need and enthusiasm from the medical community and patients to advance new treatment options that could preserve vision and alter the course of this devastating blinding disorder.